A detailed history of Raymond James & Associates transactions in Jazz Pharmaceuticals PLC stock. As of the latest transaction made, Raymond James & Associates holds 53,611 shares of JAZZ stock, worth $5.98 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
53,611
Previous 47,318 13.3%
Holding current value
$5.98 Million
Previous $5.05 Million 18.32%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$100.57 - $116.37 $632,887 - $732,316
6,293 Added 13.3%
53,611 $5.98 Million
Q2 2024

Jul 19, 2024

SELL
$103.94 - $118.98 $636,216 - $728,276
-6,121 Reduced 11.45%
47,318 $5.05 Million
Q1 2024

Apr 22, 2024

BUY
$115.19 - $132.77 $2.37 Million - $2.73 Million
20,593 Added 62.7%
53,439 $6.44 Million
Q4 2023

Jan 16, 2024

SELL
$114.26 - $136.0 $178,702 - $212,704
-1,564 Reduced 4.55%
32,846 $4.04 Million
Q3 2023

Oct 24, 2023

SELL
$122.0 - $145.31 $44,530 - $53,038
-365 Reduced 1.05%
34,410 $4.45 Million
Q2 2023

Jul 25, 2023

SELL
$122.5 - $147.16 $426,790 - $512,705
-3,484 Reduced 9.11%
34,775 $4.31 Million
Q1 2023

Apr 14, 2023

BUY
$133.98 - $160.47 $1.09 Million - $1.3 Million
8,132 Added 26.99%
38,259 $5.6 Million
Q4 2022

Feb 08, 2023

BUY
$129.72 - $159.85 $605,014 - $745,540
4,664 Added 18.32%
30,127 $4.8 Million
Q3 2022

Oct 25, 2022

SELL
$126.59 - $161.18 $440,659 - $561,067
-3,481 Reduced 12.03%
25,463 $3.39 Million
Q2 2022

Aug 12, 2022

SELL
$141.59 - $168.66 $46,441 - $55,320
-328 Reduced 1.12%
28,944 $4.52 Million
Q1 2022

May 11, 2022

SELL
$129.64 - $160.7 $1.37 Million - $1.7 Million
-10,602 Reduced 26.59%
29,272 $4.56 Million
Q4 2021

Feb 08, 2022

BUY
$119.87 - $145.67 $160,505 - $195,052
1,339 Added 3.47%
39,874 $5.08 Million
Q3 2021

Nov 02, 2021

SELL
$128.64 - $184.79 $1.89 Million - $2.72 Million
-14,724 Reduced 27.65%
38,535 $5.02 Million
Q2 2021

Aug 11, 2021

BUY
$160.2 - $186.42 $470,667 - $547,701
2,938 Added 5.84%
53,259 $9.46 Million
Q1 2021

May 14, 2021

SELL
$150.19 - $173.5 $127,361 - $147,128
-848 Reduced 1.66%
50,321 $8.27 Million
Q4 2020

Feb 12, 2021

SELL
$140.71 - $165.05 $1.42 Million - $1.67 Million
-10,126 Reduced 16.52%
51,169 $8.45 Million
Q3 2020

Nov 04, 2020

SELL
$105.46 - $144.13 $738,536 - $1.01 Million
-7,003 Reduced 10.25%
61,295 $8.74 Million
Q2 2020

Jul 28, 2020

BUY
$95.68 - $121.88 $1.18 Million - $1.51 Million
12,350 Added 22.07%
68,298 $7.54 Million
Q1 2020

Apr 21, 2020

BUY
$87.74 - $152.74 $598,474 - $1.04 Million
6,821 Added 13.88%
55,948 $5.58 Million
Q4 2019

Feb 12, 2020

BUY
$117.65 - $153.73 $1.37 Million - $1.79 Million
11,638 Added 31.04%
49,127 $7.33 Million
Q3 2019

Nov 07, 2019

BUY
$125.18 - $143.24 $15,271 - $17,475
122 Added 0.33%
37,489 $4.8 Million
Q2 2019

Aug 06, 2019

SELL
$125.55 - $144.48 $1.52 Million - $1.75 Million
-12,085 Reduced 24.44%
37,367 $5.33 Million
Q1 2019

May 06, 2019

BUY
$121.81 - $142.95 $2.18 Million - $2.56 Million
17,890 Added 56.68%
49,452 $7.07 Million
Q4 2018

Feb 11, 2019

BUY
$115.94 - $166.74 $1.43 Million - $2.05 Million
12,321 Added 64.04%
31,562 $3.91 Million
Q3 2018

Nov 14, 2018

SELL
$161.01 - $180.57 $23,990 - $26,904
-149 Reduced 0.77%
19,241 $3.24 Million
Q2 2018

Aug 14, 2018

SELL
$146.33 - $183.18 $1.98 Million - $2.48 Million
-13,531 Reduced 41.1%
19,390 $3.34 Million
Q1 2018

May 14, 2018

SELL
$135.59 - $157.16 $1.11 Million - $1.29 Million
-8,195 Reduced 19.93%
32,921 $4.97 Million
Q4 2017

Feb 14, 2018

BUY
$131.06 - $150.39 $2.39 Million - $2.74 Million
18,198 Added 79.4%
41,116 $5.54 Million
Q3 2017

Nov 13, 2017

SELL
$142.62 - $155.6 $817,783 - $892,210
-5,734 Reduced 20.01%
22,918 $3.35 Million
Q2 2017

Aug 14, 2017

BUY
N/A
28,652
28,652 $4.46 Million

Others Institutions Holding JAZZ

About Jazz Pharmaceuticals plc


  • Ticker JAZZ
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,680,700
  • Market Cap $6.99B
  • Description
  • Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement ...
More about JAZZ
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.